Nanosphere, Inc., a nanotechnology-based molecular diagnostics company founded upon technology discovered at Northwestern University, today announced that the company has closed $57 million in a Series D financing, led by Bain Capital LLC. The company will use the proceeds to commercialize the Verigene System™, a platform for user-friendly, cost-effective direct genomic testing that eliminates the need for Polymerase Chain Reaction (PCR), and to continue development and commercialization of its proprietary Biobarcode™ technology for ultra-sensitive detection of proteins and nucleic acids. The investment from Bain Capital LLC was comprised of funds from Bain Capital Ventures and Brookside Capital. Other investors in the round include Allen & Company and founding investor Lurie Investments.
